Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at WallStreetSectors.com, will continue to monitor these healthtech companies to see if the momentum continues. WallStreetSectors.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE..
Recent TVTX Stock Price: $7.85
Summary: Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.
Ed Arce analyst at H.C. Wainwright reiterates coverage on Travere Therapeutics (TVTX) stock in the energy sector with a Buy rating and has set TVTX's stock price target at $18.
TipRanks.com reports that Travere Therapeutics currently has 5 analysts offering 12-month price targets on TVTX and the consensus is a Moderate Buy rating with an average stock price target of $14.00. The most recent TVTX stock price we have is $7.85 and we are not making any TVTX forecasts at this time.
In addition, TradingView issued a sell rating for TVTX over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on TVTX. WallStreetSectors.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on TVTX, please click here >>
Charles River Labs, CRL
Recent CRL Stock Price: $199.62
Summary: Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Jack Wallace analyst at Guggenheim reiterates coverage on Charles River Labs (CRL) stock in the energy sector with a Buy rating and has set CRL's stock price target at $225.
TipRanks.com reports that Charles River Labs currently has 5 analysts offering 12-month price targets on CRL and the consensus is a Moderate Buy rating with an average stock price target of $248.20. The most recent CRL stock price we have is $199.62 and we are not making any CRL forecasts at this time.
In addition, TradingView issued a sell rating for CRL over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on CRL. WallStreetSectors.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on CRL, please click here >>
Siemens Healthineers AG, SEMHF
Recent SEMHF Stock Price: $48.20
Summary: N/A
Hassan Al-Wakeel analyst at Barclays reiterates coverage on Siemens Healthineers AG (SEMHF) stock in the energy sector with a Buy rating and has set SEMHF's stock price target at $63.86.
TipRanks.com reports that Siemens Healthineers AG currently has 5 analysts offering 12-month price targets on SEMHF and the consensus is a Moderate Buy rating with an average stock price target of $62.41. The most recent SEMHF stock price we have is $48.20 and we are not making any SEMHF forecasts at this time.
In addition, TradingView issued a Strong sell rating for SEMHF over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on SEMHF. WallStreetSectors.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SEMHF, please click here >>
The editors at WallStreetSectors.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
WallStreetSectors.com keeps investors investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to WallStreetSectors.com.
==============================================================================
